iTeos Therapeutics Stock Quote ITOS - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

15.11

Bid

14.50

Ask

24.00

Volume

401,493

14.52 Day's Range 15.16

8.20 52 Week Range 18.75

Market Cap

529.562M

Previous Close

14.66

Open

14.66

Last Trade

69123

15.11

(average)

Last Trade Time

Financial Volume

$ 5,985,269

VWAP

14.9075

Average Volume (3m)

464,210

Shares Outstanding

36,122,922

Dividend Yield

PE Ratio

-4.85

Earnings Per Share (EPS)

-3.12

Revenue

12.6M

Net Profit

-112.64M

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.iteostherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

iTeos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ITOS. The last closing price for iTeos Therapeutics was $14.66. Over the last year, iTeos Therapeutics shares have traded in a share price range of $ 8.20 to $ 18.75.

iTeos Therapeutics currently has 36,122,922 shares outstanding. The market capitalization of iTeos Therapeutics is $529.56 million. iTeos Therapeutics has a price to earnings ratio (PE ratio) of -4.85.

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.06	0.398671096346	15.05	15.16	13.06	372868	14.36900222	CS
4	-1.27	-7.75335775336	16.38	17	13.06	442805	15.02734604	CS
12	3.42	29.255774166	11.69	18.75	10.01	464210	15.57158451	CS
26	4.06	36.742081448	11.05	18.75	9.7	363468	13.79743894	CS
52	1.22	8.78329733621	13.89	18.75	8.2	395467	12.37685138	CS
156	-10.79	-41.6602316602	25.9	52.43	8.2	360345	20.73677968	CS
260	-4.59	-23.2994923858	19.7	52.43	8.2	340497	22.16281251	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SNGXSoligenix Inc	$ 7.42 (271.00%)	134.15M
ZAPPZapp Electric Vehicles Group Ltd	$ 17.9001 (93.72%)	45.51M
PEGYPineapple Energy Inc	$ 2.30 (91.67%)	77.57M
ATNF180 Life Sciences Corporation	$ 2.9017 (79.12%)	31.21M
QUREuniQure NV	$ 6.65 (75.93%)	51.5M
NVOSNovo Integrated Sciences Inc	$ 0.4874 (-35.44%)	3.12M
FAASDigiAsia Corporation	$ 3.65 (-34.17%)	49.17k
INDVIndivior PLC	$ 10.18 (-33.64%)	2.95M
CLEUChina Liberal Education Holdings Ltd	$ 0.3905 (-31.59%)	9.24M
HUBCWHub Cyber Security Ltd	$ 0.0165 (-31.25%)	1.9k
NVDANVIDIA Corporation	$ 131.38 (2.48%)	287.04M
MAXNMaxeon Solar Technologies Ltd	$ 0.2451 (-9.22%)	233.68M
TSLATesla Inc	$ 262.33 (3.71%)	160.74M
SNGXSoligenix Inc	$ 7.42 (271.00%)	134.15M
INTCIntel Corporation	$ 34.59 (1.77%)	97.81M